RTSN · ISSUER CIK 2002988
Retension Pharmaceuticals, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 6 Retension Pharmaceuticals, Inc. insiders reported $370K of open-market purchases and $0.00 of sales on SEC Form 4. The largest buyer was Keller Eric L. (CHIEF EXECUTIVE OFFICER, Director), with $250K.
↗6 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. No open-market sales in the window.
$370KInsider buying
$0.00Insider selling
+$370KNet open-market
Oct 13, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 13, 202618:12 | Oct 13, 2026 | RTSN | CHIEF EXECUTIVE OFFICER, Director | P · Buy | $12.00 | +20,800 | 423,377 | +5% | +$250K | +6.0% | -1.4% |
| Oct 13, 202618:12 | Oct 13, 2026 | RTSN | CHIEF EXECUTIVE OFFICER, Director | C · Convert | — | +41,030 | 464,407 | +10% | — | ||
| Oct 13, 202618:12 | Oct 13, 2026 | RTSN | CHIEF SCIENTIFIC OFFICER | C · Convert | — | +6,666 | 406,603 | +2% | — | ||
| Oct 13, 202618:11 | Oct 13, 2026 | RTSN | Director | C · Convert | — | +5,637 | 5,637 | New | — | ||
| Oct 13, 202618:11 | Oct 13, 2026 | RTSN | CHIEF OPERATING OFFICER | C · Convert | — | +4,115 | 4,115 | New | — | ||
| Oct 13, 202618:10 | Oct 13, 2026 | RTSN | Director | P · Buy | $12.00 | +10,000 | 10,000 | New | +$120K | +6.0% | -1.4% |
| Oct 13, 202618:10 | Oct 13, 2026 | RTSN | Director | C · Convert | — | +12,517 | 12,517 | New | — | ||
| Oct 13, 202618:10 | Oct 13, 2026 | RTSN | Director | C · Convert | — | +6,666 | 6,666 | New | — |